Evidence map›Paper›PMID 30524882›Full record

ArticleOncoimmunology

Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients.

Belinda Palermo, Ornella Franzese, Cosmo Di Donna, Mariangela Panetta, Concetta Quintarelli, Isabella Sperduti, Novella Gualtieri, Maria Laura Foddai, Enrico Proietti, Virginia Ferraresi and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 27 citations in OpenAlex.

  1. CD28/PD1 co-expression: dual impact on CD8Journal of experimental & clinical cancer research : CR · 2023
    Article
  2. T-cell repertoire diversity: friend or foe for protective antitumor response?Journal of experimental & clinical cancer research : CR · 2022
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Belinda PalermoUnit of Tumor Immunology and Immunotherapy, Department of Research, Advanced Diagnostics and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Ornella FranzeseDepartment of Systems Medicine, School of Medicine, University of Tor Vergata, Rome, Italy.
Cosmo Di DonnaUnit of Tumor Immunology and Immunotherapy, Department of Research, Advanced Diagnostics and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Mariangela PanettaUnit of Tumor Immunology and Immunotherapy, Department of Research, Advanced Diagnostics and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Concetta QuintarelliDepartment of Pediatric Haematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.
Isabella SperdutiIRCCS, Regina Elena National Cancer Institute, Rome, Italy.
Novella GualtieriUnit of Tumor Immunology and Immunotherapy, Department of Research, Advanced Diagnostics and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Maria Laura FoddaiIRCCS, Regina Elena National Cancer Institute, Rome, Italy.
Enrico ProiettiDepartment of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome.
Virginia FerraresiIRCCS, Regina Elena National Cancer Institute, Rome, Italy.
Gennaro CilibertoIRCCS, Regina Elena National Cancer Institute, Rome, Italy.
Paola NisticòUnit of Tumor Immunology and Immunotherapy, Department of Research, Advanced Diagnostics and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Superiore di Sanità · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have recently described that DNA-damage inducing drug DTIC, administered before peptide (Melan-A and gp100)-vaccination, improves anti-tumor CD8

Indexed as

CD28CD8+ T cellsChemo-immunotherapyclonotypesdacarbazinegp100human melanomaMelan-APD-1TCR diversity

Identifiers

PMID30524882
PMCPMC6279427
OpenAlexW2800309006

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.